fbpx
QQQ
-2.71
348.05
-0.78%
DIA
-5.86
344.51
-1.73%
SPY
-7.07
429.04
-1.68%
TLT
+ 2.69
140.35
+ 1.88%
GLD
-0.87
166.72
-0.52%

Analyst Ratings for Ionis Pharmaceuticals

May 7, 2021 11:11 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter:

Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago
Bullish 0 0 1 0
Somewhat Bullish 0 0 1 0
Indifferent 1 0 1 0
Somewhat Bearish 0 2 1 1
Bearish 0 0 0 0

In the last 3 months, 8 analysts have offered 12-month price targets for Ionis Pharmaceuticals. The company has an average price target of $50.19 with a high of $86.00 and a low of $35.00.

price target chart

This current average represents a 10.38% increase from the previous average price target of $56.0.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may suggest actions like “buy”, “sell”, “hold”, or similar verbage for each stock based on research compiled from the corresponding company. Analysts who suggest “buy” are telling traders to purchase the stock based on forecasted growth. On the flip side, analysts who suggest “sell” are telling traders to dump the stock because of a similarly forecasted decline. Analysts who suggest “hold” are telling investors that they see short-term or mid-term stagnation and to maintain their positions on the stock.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

Posted-In:

Analyst Ratings

Related Articles

SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $41

SVB Leerink maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $36 to $41. read more

UBS Upgrades Ionis Pharmaceuticals to Neutral, Raises Price Target to $37.5

UBS analyst Esther Rajavelu upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral and raises the price target from $33 to $37.5. read more

Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $35

Morgan Stanley maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Underweight and lowers the price target from $38 to $35. read more

Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $38

Morgan Stanley maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Underweight and lowers the price target from $43 to $38. read more